文献速递核素与放射性配体治疗肿瘤 PET/CT

基线[18F]PSMA-1007 PET的SUVmean及临床参数与计划接受[177Lu]Lu-PSMA I&T治疗的前列腺癌患者生存相关

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-05

该回顾性研究纳入103例接受[177Lu]Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者,分析治疗前[18F]PSMA-1007 PET的SUVmean等参数及临床实验室指标与总生存的关系。多变量Cox回归显示SUVmean(每单位HR 0.91)、肝转移(HR 2.37)、CRP(每mg/dl HR 1.13)和血红蛋白(每g/dl HR 0.76)为独立预后因素;风险因素数目增加与生存更差相关。

要点

  • 基线[18F]PSMA-1007 PET的SUVmean较低与接受[177Lu]Lu-PSMA I&T治疗患者的总生存缩短相关。
  • 肝转移、CRP升高和血红蛋白降低亦为总生存的独立不良预后因素。
  • 风险因素数目越多(1个 vs 2个 vs >2个)总生存越差,支持临床与影像参数用于风险分层。

核心结论

  • 较低的[18F]PSMA-1007 SUVmean、较高的CRP、较低的血红蛋白及存在肝转移与接受PSMA靶向放射性配体治疗患者的总生存缩短相关。
  • 早期风险因素模型显示风险因素数目增加与更差结局相关,强调临床与影像参数对充分风险分层的重要性。

研究设计与样本

  • 回顾性分析103例接受[177Lu]Lu-PSMA I&T治疗的转移性去势抵抗性前列腺癌患者。
  • 计算治疗前[18F]PSMA-1007 PET的SUVmean、SUVmax、PSMA阳性肿瘤体积(TV)及总病灶PSMA(PSMA-TV×SUVmean)。
  • 收集RLT前血红蛋白、C反应蛋白(CRP)、乳酸脱氢酶(LDH)、天冬氨酸氨基转移酶(AST)及碱性磷酸酶(AP)实验室值。
  • 采用单变量Cox回归、多变量Cox回归及Kaplan-Meier分析,以总生存(OS)为终点。
  • 构建包含多变量分析中所有显著因素的风险因素(RF)模型,评估风险因素数目增加是否改善风险分层。

主要发现

  • 共48例患者死亡,中位OS为16个月。
  • 单变量Cox回归中,SUVmean、CRP、LDH、血红蛋白及肝转移的存在与OS显著相关。
  • 多变量Cox回归中,OS的显著预后因素为SUVmean(每单位,HR 0.91;P=0.04)、肝转移的存在(HR 2.37;P=0.03)、CRP(每mg/dl,HR 1.13;P=0.003)及血红蛋白(每g/dl,HR 0.76;P<0.01)。
  • Kaplan-Meier分析显示,SUVmean低于或高于中位SUVmean 9.4的患者间生存分离显著(9个月 vs 19个月,HR 0.57;P=0.03)。
  • 仅1个RF的患者(中位OS未达到)生存最长, compared to 2个RF患者(11个月;HR 2.43,95%CI 1.07-5.49,P=0.02)或超过2个RF患者(7个月;HR 3.37,95%CI 1.62-7.03,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quantification of [68 Ga]-labeled PSMA PET predicts response in patients with prostate cancer (PC) who undergo PSMA-targeted radioligand therapy (RLT). Given the increasing use [18F]-labeled radiotracers, we aimed to determine whether the uptake derived from [18F]PSMA-1007 PET can also identify responders and to assess its prognostic value relative to established clinical parameters. METHODS: We retrospectively analyzed 103 patients with metastatic, castration-resistant PC who were treated with [177Lu]Lu-PSMA I&T. We calculated SUVmean, SUVmax, PSMA-avid tumor volume (TV), and total lesion PSMA (defined as PSMA-TV*SUVmean) on pre-therapeutic [18F]PSMA-1007 PET. Laboratory values for hemoglobin, C-reactive protein (CRP), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alkaline phosphatase (AP) were also collected prior to RLT. We performed univariable Cox regression followed by multivariable and Kaplan-Meier analyses with overall survival (OS) serving as endpoint. Last, we also computed a risk factor (RF) model including all items reaching significance on multivariable analysis to determine whether an increasing number of RFs can improve risk stratification. RESULTS: A total of 48 patients died and median OS was 16 months. On univariable Cox regression, SUVmean, CRP, LDH, hemoglobin, and the presence of liver metastases were significantly associated with OS. On multivariable Cox regression, the following significant prognostic factors for OS were identified: SUVmean (per unit, HR, 0.91; P = 0.04), the presence of liver metastases (HR, 2.37; P = 0.03), CRP (per mg/dl, HR, 1.13; P = 0.003), and hemoglobin (per g/dl, HR, 0.76; P < 0.01). Kaplan-Meier analysis showed significant separation between patients with a SUVmean below or above a median SUVmean of 9.4 (9 vs 19 months, HR 0.57; P = 0.03). Of note, patients with only one RF (median OS not reached) showed longest survival compared to patients with two (11 months; HR 2.43 95% CI 1.07-5.49, P = 0.02) or more than two RFs (7 months; HR 3.37 95% CI 1.62-7.03, P < 0.001). CONCLUSION: A lower SUVmean derived from [18F]PSMA-1007, higher CRP, lower hemoglobin, and the presence of liver metastases are associated with reduced OS in patients undergoing RLT. An early RF model also demonstrated that an increasing number of those factors is linked to worse outcome, thereby emphasizing the importance of clinical and imaging parameters for adequate risk stratification.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Hüttmann T, Seitz AK, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023. PMID: 37272956. doi:10.1007/s00259-023-06281-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。